There are about half a million C. diff infections every year in the United States. About 30,000 people die from them annually. But if you’ve had C. diff, you’re more likely to get it again. About 1 in ...

There are trillions of bacteria that live in your colon. Most of them are harmless and many are actually helpful, supporting digestion and keeping your immune system strong. C. diff is one type of ...

Prompt treatment with fecal transplant can improve survival among critically ill C. difficile patients 14 of 18 patients with life-threatening C. diff survived after a fecal transplant Antibiotics ...

A new study from the University of Minnesota Medical School has demonstrated that fecal microbiota transplantation (FMT) can rapidly reverse systemic inflammation and improve survival in patients with ...

While antibiotics and gastric acid-suppressing drugs are known to be risk factors for Clostridioides difficile infection, other commonly prescribed non-antibiotic drugs were found to be culprits, ...

DEAR DR. ROACH: I read your recent column about a person who was refusing antibiotics due to a fear of a Clostridioides difficile (C. diff) recurrence. I am interested in your thoughts regarding ...

The diseases were removed from a list of tests the agency conducts for state and local health departments. Experts worry that with drastic staff reductions, the testing may not resume. By Apoorva ...

Toyota’s reputation for producing reliable, practical, and durable vehicles is backed up by decades of conservative engineering and consistent quality control. As the automaker develops its lineup of ...

Her son had been sick for four months when Blanca Morales started asking about a transplant. It had started with a case of strep throat from Mundo’s first-grade class — routine enough, treatable with ...

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile, the leading cause of healthcare and antibiotic-associated diarrhea in the US and ...

Crestone, Inc. (“Crestone”) today announced recent publication in the leading infectious disease journal, The Lancet Infectious Diseases, of positive results from a Phase 2 clinical trial evaluating ...